Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil
| Autor: | Marta Dell'Orso, Natalia Riva, Graciela Calle, Paulo Cáceres Guido, Norma Sberna, Paula Schaiquevich, Mariana Gatto |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Latin Americans Pharmacist Pharmacology (nursing) Context (language use) Medical Marijuana Pharmacy Pharmacists 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Health care medicine Cannabidiol Humans 030212 general & internal medicine Child Cannabis Pharmacology Protocol (science) business.industry Scientific progress Clinical pharmacy Latin America Clinical research Family medicine business |
| Zdroj: | Journal of the American Pharmacists Association. 60:212-215 |
| ISSN: | 1544-3191 |
| DOI: | 10.1016/j.japh.2019.09.012 |
| Popis: | Objective Cannabis sativa was introduced in Latin America in the 16th century. Nevertheless, many years have elapsed, and scientific progress and the medicinal use of C sativa have been restricted by the national laws of the countries in the region. Summary In Argentina, the first law on medical cannabis, approved in 2017 (#17,350), establishes a regulatory framework for the medical use and scientific research of this plant and its derivatives. In 2018, the first clinical research protocol in Latin America was approved at Hospital de Pediatria Garrahan (Buenos Aires, Argentina) to evaluate the efficacy and safety of cannabidiol (CBD) oil for the treatment of pediatric patients with refractory epilepsy. In this context, the role of pharmacists in the health care system related to the study protocol and the medicinal use of CBD has evolved from dispensing to active participation in clinical follow-up and research protocols. Conclusion Considering this experience, here we discuss the active role of the clinical pharmacist in the use of medicinal cannabis. Medicinal cannabis should be controlled in a legal framework based on clinical evidence, and the participation of the pharmacist in research and clinical protocols, as well as the dispensing and provision of information on the medicinal products should be emphasized in the clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|